Fellowship application season is upon us!
@UMKC and Saint Luke's @MidAmericaHeart offers:
✴️ 3 yr CV fellowship
✴️ 4 yr T32 clinical/research track
✴️ Advanced HF
✴️ EP
✴️ Interventional
✴️ Structural
✴️ CV Imaging
✴️ Prevention
Apply today!
https://t.co/7V9IO7eicX
The Cardiovascular Structural Intervention Fellowship through @UMKCMedSchool and @MidAmericaheart accepts one candidate per academic year. Fellows benefit from getting hands-on training from renowned specialists.
Learn more and request an application now: https://t.co/ZhEIgzthee
The Cardiovascular Structural Intervention Fellowship through @UMKCMedSchool and @MidAmericaheart accepts one candidate per academic year. Fellows benefit from getting hands-on training from renowned specialists.
Learn more and request an application now: https://t.co/ZhEIgzthee
Congratulations to Rich Liekweg, BJC Health System CEO, who announced his plans to retire on October 1, 2025.
BJC is pleased to announce that Nick Barto, current BJC Health System President, will succeed Rich as President and CEO of BJC Health System: https://t.co/wpXdGLElw2
Understanding patient-reported outcomes in obstructive hypertrophic cardiomyopathy (oHCM) is vital for managing treatment effectively.
We recently validated the Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) in this population. Here’s why it matters:
A quick🧵
https://t.co/I6AI4zSCkw
At #ESCHF2025 🇷🇸 @MidAmericaHeart fellow Dr Omar Cantu-Martinez presents #CAREHKinHF real-world registry: >2,300 HF pts w/ hyperK risk with 9% on clinician selected patiromer.
Reduced severe HK and trend toward more optimal GDMT.
Take-home: early K⁺ control keeps GDMT on & protects heart + kidneys
Grateful for the opportunity to work with @Amgen in collaboration with @cardiometalli@MidAmericaHeart as part of the LATTICE Consortium to address implementation of cardiometabolic therapies and stepping into the gaps.
Special focus issue in @JACCJournals this week on Cardiac Amyloidosis.
Many important articles! Sharing my editorial with Joban Vaishnav from @JohnsHopkins
https://t.co/Q2EBUABhw0
One of the defining aspects of our fellowship are our accomplished alumni. As a part of our fellowship research day, Dr. Chhatriwalla honored us with a noon conference on advancements in ViV TAVR and bioprosthetic valve fracture! @akcmahi@venumenon10
Art Still, a former @Chiefs defensive end, has dedicated himself to increasing awareness for ATTR amyloidosis ever since his diagnosis in 2023.
@TODAYshow spoke with Dr. Brett Sperry, a @MidAmericaHeart cardiologist, to discuss the rare genetic condition: https://t.co/qbMKv9M20t
Outside of her work as an oncologist, Dr. Juliet Appiah helps cancer patients in her home country of Ghana.
Dr. Appiah spoke with @KSHB41 about her passion for giving back to her home country and raising awareness for all types of cancer. Watch now: https://t.co/GSMeSI9bm3
Here are some reasons why you should train with us in Cardiovascular Disease at the University of Missouri-Kansas City School of Medicine program @MidAmericaHeart@saintlukeskc!
Semaglutide and obesity related HFpEF
Patients with atrial fibrillation and obesity HFpEF are generally more burdened/congested at baseline and also may benefit more from GLP1 in health status and walking distance.
@MkosiborodMD@MidAmericaHeart
https://t.co/Pd16sJe54A
Semaglutide and obesity HFpEF
Echo markers
Improved LA volume reduction and markers of diastolic function with GLP1 compared to placebo.
@mvaduganathan@BiykemB@MkosiborodMD